Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

DBVT Stock - DBV Technologies S A Stock Trading


home / stock / dbvt

DBVT DBVT Quote DBVT Short DBVT News DBVT Articles DBVT Message Board

MWN AI Summary *

DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company headquartered in Paris, France, focused on developing innovative treatments for allergies and immunological diseases. Its primary platform technology, "Viaskin," is a proprietary epicutaneous immunotherapy (EPIT) designed to deliver therapeutic molecules through the skin using an adhesive patch. This method aims to decrease the risk of systemic reactions often associated with traditional allergy treatments, such as injections or oral medications.

The company’s lead product candidate, Viaskin Peanut, has garnered significant attention as it targets peanut allergies, a prevalent and often dangerous condition affecting millions worldwide. As of late 2023, DBV was advancing through clinical trials with a focus on demonstrating the efficacy and safety of Viaskin Peanut in desensitizing patients to peanut allergens. DBV is working diligently to bring this groundbreaking product to market, having faced various regulatory hurdles in previous years, including setbacks from the U.S. Food and Drug Administration (FDA) regarding its clinical data.

In addition to peanut allergies, DBV is exploring potential applications of its Viaskin platform for other food allergies, such as milk and egg allergies, and for conditions like atopic dermatitis and environmental allergies. The company has been actively engaging in partnerships and collaborations to enhance its research capabilities and expedite the development of its therapies.

Financially, DBV Technologies has experienced volatility in its stock price, reflecting investor sentiment and the outcomes of its clinical trials. Analysts remain cautiously optimistic about the company’s potential, particularly if it can successfully navigate the clinical landscape and secure regulatory approvals. Overall, DBV Technologies stands at the forefront of allergy treatment innovation, striving to improve the quality of life for patients suffering from debilitating allergic conditions.

MWN AI Analysis *

DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company pioneering the development of treatments for food allergies through innovative immunotherapy. Given the current market landscape and DBV's strategic positioning, a nuanced analysis is essential for prospective investors.

As of late 2023, DBV Technologies has faced considerable challenges, particularly in the wake of setbacks with its flagship product, Viaskin peanut. The company has been working diligently to address regulatory concerns, notably from the U.S. Food and Drug Administration (FDA), which has prompted delays in clinical trials. These regulatory hurdles have resulted in heightened volatility in stock performance, presenting both risk and opportunity for investors.

A key factor to consider is the demand for innovative therapies in the allergy market, which remains robust. As consumer awareness of food allergies continues to rise, so does the market potential for DBV's unique approach to desensitization therapies. Investors should closely monitor upcoming trial results and any developments regarding regulatory approval, as successful outcomes could significantly bolster the stock’s long-term value.

From a financial perspective, DBV Technologies has a relatively high burn rate typical for clinical-stage companies; thus, managing cash flow will be critical. Investors should keep an eye on upcoming funding rounds or partnerships that could provide the necessary capital to advance its clinical programs.

Given the inherent risks associated with biopharmaceutical investments, potential investors might consider a cautiously optimistic stance on DBV Technologies. Long-term holders should be prepared for volatility, while those looking for short-term gains may need to approach with heightened caution. Overall, a watchful eye on regulatory developments and clinical trial results will be crucial in navigating investment decisions concerning DBV Technologies.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | DBV Technologies S.A. (NASDAQ:DBVT)

DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. Its method of delivering biologically active compounds to the immune system is through self-administered and non-invasive products. It also explores potential applications of its platform in vaccines and other immune diseases.

Quote | DBV Technologies S.A. (NASDAQ:DBVT)

Last:$11
Change Percent: -5.21%
Open:$11.15
Close:$11
High:$11.33
Low:$10.895
Volume:9,198
Last Trade Date Time:07/09/2025 03:25:22 pm

News | DBV Technologies S.A. (NASDAQ:DBVT)

  • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years Old

    Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffr...

    • June 25, 2025 04:15:00 pm

    • |
    • GlobeNewswire
    • |
      • DBVT Stock
      • DBVT Quote
      • DBVT Short
      • DBVT News
      • DBVT Articles
      • DBVT Message Board
  • DBV Technologies to Participate in Upcoming EAACI Congress 2025

    Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announce...

    • June 12, 2025 04:05:00 pm

    • |
    • GlobeNewswire
    • |
      • DBVT Stock
      • DBVT Quote
      • DBVT Short
      • DBVT News
      • DBVT Articles
      • DBVT Message Board

Message Board Posts | DBV Technologies S.A. (NASDAQ:DBVT)

Subject By Source When
$AIHS WITHDRAWALS REGISTRATION https://investorshub.advfn.com/boards/read_msg.as TheFinalCD investorshub 12/30/2022 11:06:40 PM
1.6m shares short,better cover your nuts shorties;-) 81vette investorshub 12/23/2022 3:37:25 PM
P&D but they are all over NASDAQ and subslover investorshub 12/23/2022 3:21:49 PM
I got hooked yesterday on $YGMZ Pedro2004 investorshub 12/23/2022 3:13:57 PM
i hope shorts get their nuts squeezed off,lol 81vette investorshub 12/23/2022 3:12:18 PM

MWN AI FAQ **

How does DBV Technologies S.A. DBVT plan to improve its clinical trial outcomes for its Viaskin peanut product in the upcoming quarters?

DBV Technologies S.A. plans to improve its clinical trial outcomes for the Viaskin peanut product by enhancing patient enrollment strategies, refining trial protocols, and implementing comprehensive data monitoring to ensure timely and accurate results in the upcoming quarters.

What are the key financial metrics for DBV Technologies S.A. DBVT that investors should focus on for assessing its growth potential?

Investors should focus on key financial metrics for DBV Technologies S.A. (DBVT) such as revenue growth, operating loss trends, cash flow position, R&D expenditures, clinical trial milestones, and market penetration potential to assess its growth potential.

Can you provide insights into any recent partnerships or collaborations involving DBV Technologies S.A. DBVT that may enhance its market position?

As of my last update in October 2023, DBV Technologies S.A. has formed strategic partnerships aimed at advancing its desensitization therapies, potentially enhancing its market position and broadening its reach in the therapeutic landscape for food allergies.

What challenges does DBV Technologies S.A. DBVT anticipate in the regulatory approval process for its lead product, and how are they addressing these challenges?

DBV Technologies S.A. anticipates challenges in demonstrating the efficacy and safety of its lead product, particularly in meeting rigorous regulatory standards, and is addressing these through enhanced clinical trial designs, ongoing engagement with regulatory agencies, and strategic data analysis.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get DBVT Alerts

News, Short Squeeze, Breakout and More Instantly...

DBV Technologies S.A. Company Name:

DBVT Stock Symbol:

NASDAQ Market:

-5.21% G/L:

$11 Last:

9,198 Volume:

$11.15 Open:

$11 Close:

DBV Technologies S.A. Website:

DBV Technologies S.A. Logo

Ad

Trending Stock Alerts
RECENT DBVT NEWS
  • DBVT - DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years Old

    Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffr...

  • DBVT - DBV Technologies to Participate in Upcoming EAACI Congress 2025

    Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announce...

  • DBVT - DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

    Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-s...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get DBVT Alerts

Get DBVT Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1